This year's Bio International Convention, also known as Bio USA, is seeing a surge in participation from South Korean pharmaceutical and biotech companies. The absence of Chinese rivals has created an opportunity for these companies to showcase their latest innovations and forge new partnerships. With a record-breaking number of more than 20,000 biotechnology and pharma leaders registered, the event in San Diego will host 47 Korean companies, including major players like Samsung Biologics, Celltrion, SK Bioscience, and Lotte Biologics. This surge in Korean participation comes at a time when leading Chinese companies have chosen to boycott the convention due to escalating US-China tensions and the passage of the US Biosecure Act of 2024. San Diego, as one of the top three biotech clusters in the US, offers a promising platform for Korean firms to expand their presence. The growing interest from multinational pharmaceutical companies in Korean biotech firms indicates a shift towards more two-way communication and recognition of Korean technology in new drug development. Major exhibitors like Samsung Biologics and Celltrion are leveraging the convention to showcase their latest achievements, including the construction of new production facilities and the introduction of innovative biotechnology products. The Korean Pavilion at Bio USA, jointly operated by KoreaBio and the Korea Trade-Investment Promotion Agency, has been a key platform for Korean companies to promote themselves and engage with foreign clients.